论文部分内容阅读
目的探讨脑蛋白水解物治疗缺血性脑血管病的临床疗效及对神经功能的影响。方法 86例患者均为本院2014年12月至2016年6月期间收治的缺血性脑血管病病例,按照双盲法将其分为两组。对照组患者给予复方丹参注射液治疗,观察组患者在此基础上给予脑蛋白水解物治疗。4个疗程后,观察两组的治疗效果,并采用神经功能缺损评分(NHISS)对患者治疗前后神经功能改善情况展开分析。结果 4个疗程后,观察组患者治疗效果显著优于对照组,差异有统计学意义(P<0.05)。两组患者治疗前NIHSS评分无差异,但治疗后均有明显改善,且观察组显著优于对照组,差异有统计学意义(P<0.05)。结论脑蛋白水解物治疗缺血性脑血管病的临床疗效较好,且能够显著改善患者神经功能,安全性高,值得推广。
Objective To investigate the clinical efficacy of brain protein hydrolyzate in the treatment of ischemic cerebrovascular disease and its influence on neurological function. Methods Totally 86 patients were admitted to our hospital from December 2014 to June 2016. The patients were divided into two groups according to the double-blind method. Patients in the control group were treated with compound Danshen injection and patients in the observation group were treated with brain protein hydrolysates on the basis of this. After 4 courses of treatment, the therapeutic effects of the two groups were observed, and the neurological deficits (NHISS) were used to analyze the neurological function of the patients before and after treatment. Results After 4 courses of treatment, the treatment effect of the observation group was significantly better than that of the control group, with significant difference (P <0.05). There was no difference in NIHSS score between the two groups before treatment, but both groups showed significant improvement after treatment, and the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of brain protein hydrolyzate in the treatment of ischemic cerebrovascular disease is good, and can significantly improve the neurological function of patients with high safety, which is worth promoting.